NASDAQ:ILMN Illumina (ILMN) Stock Price, News & Analysis $109.30 +1.66 (+1.54%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$109.39 +0.09 (+0.08%) As of 07/25/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Illumina Stock (NASDAQ:ILMN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Illumina alerts:Sign Up Key Stats Today's Range$106.40▼$110.0550-Day Range$79.37▼$109.3052-Week Range$68.70▼$156.66Volume1.94 million shsAverage Volume2.25 million shsMarket Capitalization$17.30 billionP/E RatioN/ADividend YieldN/APrice Target$125.11Consensus RatingHold Company Overview Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California. Read More Illumina Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreILMN MarketRank™: Illumina scored higher than 93% of companies evaluated by MarketBeat, and ranked 74th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingIllumina has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 8 buy ratings, 9 hold ratings, and 2 sell ratings.Amount of Analyst CoverageIllumina has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Illumina's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth14.41% Earnings GrowthEarnings for Illumina are expected to grow by 14.41% in the coming year, from $4.51 to $5.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Illumina is -18.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Illumina is -18.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioIllumina has a PEG Ratio of 2.14. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIllumina has a P/B Ratio of 7.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Illumina's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.53% of the float of Illumina has been sold short.Short Interest Ratio / Days to CoverIllumina has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Illumina has recently increased by 10.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIllumina does not currently pay a dividend.Dividend GrowthIllumina does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.11 Percentage of Shares Shorted4.53% of the float of Illumina has been sold short.Short Interest Ratio / Days to CoverIllumina has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Illumina has recently increased by 10.95%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News Sentiment1.10 News SentimentIllumina has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Illumina this week, compared to 19 articles on an average week.Search Interest20 people have searched for ILMN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows4 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Illumina insiders have bought more of their company's stock than they have sold. Specifically, they have bought $495,381.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of Illumina is held by insiders.Percentage Held by Institutions89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Illumina's insider trading history. Receive ILMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter. Email Address ILMN Stock News HeadlinesCathie Wood's Bold AI and Genomics Playbooks RevealedJuly 24 at 11:29 AM | finance.yahoo.comCathie Wood Pours Millions into Nvidia and Biotech, Dumps Rocket LabJuly 24 at 11:29 AM | finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 27 at 2:00 AM | Paradigm Press (Ad)Q2 Earnings Estimate for Illumina Issued By Leerink PartnrsJuly 20, 2025 | americanbankingnews.comIllumina Stock: What Went Wrong And Why It's Best To Stay AwayJuly 17, 2025 | benzinga.comIllumina Stock: What Went Wrong And Why It's Best To Stay AwayJuly 17, 2025 | benzinga.comNotable healthcare headlines for the week: Trump’s tariff threat, Merck, UnitedHealth and Moderna in focusJuly 13, 2025 | msn.comNotable analyst calls this week: Tesla, Microsoft and Illumina among top picksJuly 12, 2025 | msn.comSee More Headlines ILMN Stock Analysis - Frequently Asked Questions How have ILMN shares performed this year? Illumina's stock was trading at $133.63 at the beginning of the year. Since then, ILMN stock has decreased by 18.2% and is now trading at $109.30. How were Illumina's earnings last quarter? Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings results on Thursday, May, 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. The company's revenue was down 1.4% on a year-over-year basis. Read the conference call transcript. Does Illumina have any subsidiaries? Illumina subsidiaries include Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and others. Who are Illumina's major shareholders? Top institutional shareholders of Illumina include PGGM Investments (0.73%), Swedbank AB (0.33%), Assenagon Asset Management S.A. (0.25%) and Aberdeen Group plc (0.21%). Insiders that own company stock include Susan H Tousi, Jacob Thaysen, Aimee L Hoyt and Alexander Aravanis. View institutional ownership trends. How do I buy shares of Illumina? Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Illumina own? Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Alphabet (GOOG). Company Calendar Last Earnings5/08/2025Today7/27/2025Next Earnings (Estimated)7/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:ILMN CIK1110803 Webwww.illumina.com Phone(858) 202-4500Fax858-202-4766Employees9,030Year Founded1998Price Target and Rating Average Price Target for Illumina$125.11 High Price Target$200.00 Low Price Target$80.00 Potential Upside/Downside+14.5%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)($6.07) Trailing P/E RatioN/A Forward P/E Ratio24.24 P/E Growth2.14Net Income-$1.22 billion Net Margins-22.25% Pretax Margin-20.48% Return on Equity25.54% Return on Assets8.62% Debt Debt-to-Equity Ratio0.63 Current Ratio1.86 Quick Ratio1.48 Sales & Book Value Annual Sales$4.37 billion Price / Sales3.96 Cash Flow$4.69 per share Price / Cash Flow23.30 Book Value$14.96 per share Price / Book7.31Miscellaneous Outstanding Shares158,300,000Free Float154,184,000Market Cap$17.30 billion OptionableOptionable Beta1.36 Social Links 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:ILMN) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Illumina, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Illumina With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.